Inhibrx (INBX) Competitors $12.32 -0.01 (-0.08%) Closing price 04:00 PM EasternExtended Trading$12.28 -0.04 (-0.37%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INBX vs. DNTH, ANAB, XERS, ABUS, CDXC, ARVN, KALV, TRVI, KROS, and VECTShould you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include Dianthus Therapeutics (DNTH), AnaptysBio (ANAB), Xeris Biopharma (XERS), Arbutus Biopharma (ABUS), ChromaDex (CDXC), Arvinas (ARVN), KalVista Pharmaceuticals (KALV), Trevi Therapeutics (TRVI), Keros Therapeutics (KROS), and VectivBio (VECT). These companies are all part of the "pharmaceutical products" industry. Inhibrx vs. Dianthus Therapeutics AnaptysBio Xeris Biopharma Arbutus Biopharma ChromaDex Arvinas KalVista Pharmaceuticals Trevi Therapeutics Keros Therapeutics VectivBio Inhibrx (NASDAQ:INBX) and Dianthus Therapeutics (NASDAQ:DNTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership. Which has preferable earnings and valuation, INBX or DNTH? Dianthus Therapeutics has higher revenue and earnings than Inhibrx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibrx$200K911.63-$154.96MN/AN/ADianthus Therapeutics$6.24M111.72-$43.56M-$2.60-8.34 Do analysts prefer INBX or DNTH? Dianthus Therapeutics has a consensus target price of $54.33, indicating a potential upside of 150.58%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than Inhibrx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Do institutionals & insiders hold more shares of INBX or DNTH? 82.5% of Inhibrx shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 22.2% of Inhibrx shares are owned by company insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer INBX or DNTH? Inhibrx received 5 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 96.30% of users gave Dianthus Therapeutics an outperform vote while only 58.49% of users gave Inhibrx an outperform vote. CompanyUnderperformOutperformInhibrxOutperform Votes3158.49% Underperform Votes2241.51% Dianthus TherapeuticsOutperform Votes2696.30% Underperform Votes13.70% Is INBX or DNTH more profitable? Inhibrx has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,250.32%. Dianthus Therapeutics' return on equity of -21.68% beat Inhibrx's return on equity.Company Net Margins Return on Equity Return on Assets InhibrxN/A -113.74% -80.56% Dianthus Therapeutics -1,250.32%-21.68%-20.88% Does the media favor INBX or DNTH? In the previous week, Inhibrx had 2 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 6 mentions for Inhibrx and 4 mentions for Dianthus Therapeutics. Inhibrx's average media sentiment score of 1.69 beat Dianthus Therapeutics' score of 1.13 indicating that Inhibrx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Dianthus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDianthus Therapeutics beats Inhibrx on 9 of the 16 factors compared between the two stocks. Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$183.79M$2.95B$5.49B$7.94BDividend YieldN/A1.89%5.11%4.23%P/E RatioN/A30.1722.5818.55Price / Sales911.63492.83397.25103.00Price / CashN/A168.6838.1834.62Price / BookN/A3.176.704.26Net Income-$154.96M-$72.35M$3.23B$248.39M7 Day Performance5.13%0.65%1.26%1.27%1 Month Performance-10.36%7.90%3.75%3.85%1 Year Performance-63.28%-22.99%15.78%5.23% Inhibrx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx2.5616 of 5 stars$12.32-0.1%N/A-63.8%$178.34M$200,000.000.00166Short Interest ↓Positive NewsDNTHDianthus Therapeutics1.7349 of 5 stars$20.45+4.9%$54.33+165.7%+2.3%$656.98M$6.24M-8.1880Upcoming EarningsNews CoveragePositive NewsANABAnaptysBio2.5205 of 5 stars$20.62+0.3%$33.63+63.1%-8.7%$632.35M$91.28M-3.39100Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsXERSXeris Biopharma3.5759 of 5 stars$4.02-2.2%$6.10+51.7%+161.1%$618.84M$203.07M-8.93290Upcoming EarningsNews CoveragePositive NewsABUSArbutus Biopharma2.0078 of 5 stars$3.21+1.9%$5.50+71.3%+30.0%$614.65M$6.17M-7.4690CDXCChromaDex2.3331 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Upcoming EarningsAnalyst ForecastARVNArvinas3.39 of 5 stars$8.75+1.7%$34.33+292.4%-69.7%$601.76M$263.40M-3.16420Earnings ReportShort Interest ↑News CoverageGap DownHigh Trading VolumeKALVKalVista Pharmaceuticals4.3785 of 5 stars$12.01+0.1%$24.83+106.8%+21.3%$597.09MN/A-3.30100Positive NewsTRVITrevi Therapeutics3.5998 of 5 stars$6.02-0.8%$17.56+191.7%+135.8%$582.03MN/A-13.6820Upcoming EarningsNews CoveragePositive NewsKROSKeros Therapeutics3.0986 of 5 stars$14.30+1.6%$40.33+182.1%-74.4%$580.04M$3.55M-2.74100Upcoming EarningsPositive NewsVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading Volume Related Companies and Tools Related Companies Dianthus Therapeutics Alternatives AnaptysBio Alternatives Xeris Biopharma Alternatives Arbutus Biopharma Alternatives ChromaDex Alternatives Arvinas Alternatives KalVista Pharmaceuticals Alternatives Trevi Therapeutics Alternatives Keros Therapeutics Alternatives VectivBio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INBX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INBX Stock Free INBX Stock Alerts